Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-160X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis ; volume:37 ; number:3 ; day:20 ; month:12 ; year:2016 ; pages:369-376 ; date:3.2017
Rheumatology international ; 37, Heft 3 (20.12.2016), 369-376, 3.2017
- Schlagwort
-
Infektion
Infektiologie
- Urheber
-
Kawashima, Hirotoshi
- Beteiligte Personen und Organisationen
-
Kagami, Shin-ichiro
Kashiwakuma, Daisuke
Takahashi, Kentaro
Yokota, Masaya
Furuta, Shunsuke
Iwamoto, Itsuo
SpringerLink (Online service)
- DOI
-
10.1007/s00296-016-3631-z
- URN
-
urn:nbn:de:1111-2017030913654
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kawashima, Hirotoshi
- Kagami, Shin-ichiro
- Kashiwakuma, Daisuke
- Takahashi, Kentaro
- Yokota, Masaya
- Furuta, Shunsuke
- Iwamoto, Itsuo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Biologic agents in juvenile spondyloarthropathies
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Anesthetic agents and elderly
Dopaminergic Agents in Rheumatoid Arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Biologic agents in juvenile spondyloarthropathies
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Anesthetic agents and elderly
Dopaminergic Agents in Rheumatoid Arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Biologic agents in juvenile spondyloarthropathies
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Anesthetic agents and elderly